[go: up one dir, main page]

AR084500A1 - Tableta multicapa para tratar la infeccion por hiv en un humano - Google Patents

Tableta multicapa para tratar la infeccion por hiv en un humano

Info

Publication number
AR084500A1
AR084500A1 ARP110104318A ARP110104318A AR084500A1 AR 084500 A1 AR084500 A1 AR 084500A1 AR P110104318 A ARP110104318 A AR P110104318A AR P110104318 A ARP110104318 A AR P110104318A AR 084500 A1 AR084500 A1 AR 084500A1
Authority
AR
Argentina
Prior art keywords
layer
tablet
human
hiv infection
treat hiv
Prior art date
Application number
ARP110104318A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084500(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR084500A1 publication Critical patent/AR084500A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Tabletas multicapas que contienen rilpivirina clorhidrato, emtricitabina y tenofivir disoproxil fumarato. Las tabletas son útiles para el tratamiento del HIV.Reivindicación 1: Una tableta que comprende una primera capa y una segunda capa donde: a) la primera capa comprende rilpivirina HCI y está sustancialmente libre de tenofovir disoproxil fumarato; b) la segunda capa comprende tenofovir disoproxil fumarato y está sustancialmente libre de rilpivirina HCI; y c) la tableta comprende además emtricitabina. Reivindicación 18: La tableta de acuerdo con cualquiera de las reivindicaciones 1 - 16 que además comprende una tercera capa que está interpuesta y que separa la primera capa de la segunda capa. Reivindicación 19: La tableta de acuerdo con la reivindicación 18 en la cual la tercera capa comprende lactosa monohidrato y/o celulosa microcristalina.
ARP110104318A 2010-11-19 2011-11-18 Tableta multicapa para tratar la infeccion por hiv en un humano AR084500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19

Publications (1)

Publication Number Publication Date
AR084500A1 true AR084500A1 (es) 2013-05-22

Family

ID=45094284

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104318A AR084500A1 (es) 2010-11-19 2011-11-18 Tableta multicapa para tratar la infeccion por hiv en un humano
ARP200103214A AR123409A2 (es) 2010-11-19 2020-11-19 Composiciones terapéuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200103214A AR123409A2 (es) 2010-11-19 2020-11-19 Composiciones terapéuticas

Country Status (36)

Country Link
US (1) US10857102B2 (es)
EP (2) EP2640362B2 (es)
JP (2) JP2014500261A (es)
KR (1) KR101923103B1 (es)
CN (2) CN103491948B (es)
AP (1) AP3816A (es)
AR (2) AR084500A1 (es)
AU (3) AU2011329642B2 (es)
BR (1) BR112013012245B1 (es)
CA (1) CA2818097C (es)
CL (1) CL2013001402A1 (es)
CO (1) CO6761300A2 (es)
CR (1) CR20130293A (es)
DK (1) DK2640362T4 (es)
EA (2) EA025852B1 (es)
EC (2) ECSP13012700A (es)
ES (1) ES2524408T5 (es)
HK (1) HK1206592A1 (es)
HR (1) HRP20140946T1 (es)
IL (1) IL226300B (es)
MA (1) MA34735B1 (es)
ME (1) ME01980B (es)
MX (1) MX347512B (es)
MY (1) MY185604A (es)
NZ (1) NZ610729A (es)
PE (3) PE20140163A1 (es)
PH (1) PH12013501002A1 (es)
PL (1) PL2640362T5 (es)
PT (1) PT2640362E (es)
RS (1) RS53691B1 (es)
SG (3) SG10201509521WA (es)
SM (1) SMT201400150B (es)
TW (1) TWI556840B (es)
UA (1) UA114075C2 (es)
WO (1) WO2012068535A1 (es)
ZA (1) ZA201304481B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201100293A1 (ru) 2003-01-14 2011-08-30 Джилид Сайэнс, Инк. Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AP3816A (en) 2010-11-19 2016-09-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
SMT201600476T1 (it) 2011-08-16 2017-03-08 Gilead Sciences Inc Tenofovir alafenammide emifumarato
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
PE20151499A1 (es) 2012-12-21 2015-10-29 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
EP2832351A1 (en) * 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
SI3346995T1 (sl) * 2015-11-09 2019-11-29 Gilead Sciences Inc Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
CA3067147A1 (en) 2017-06-30 2019-01-03 Viiv Healthcare Company Combination and uses and treatments thereof
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
BR112021026916A2 (pt) * 2019-07-03 2022-05-10 Janssen Sciences Ireland Unlimited Co Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ250842A (en) 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003045327A2 (en) 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
EA201100293A1 (ru) * 2003-01-14 2011-08-30 Джилид Сайэнс, Инк. Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
DK1632232T6 (da) 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1933815A2 (en) 2005-10-14 2008-06-25 Microdose Technologies Inc. Pharmaceutical packaging of an oral dosage combination
AP2008004533A0 (en) 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
PL2487161T5 (pl) * 2007-02-23 2024-09-09 Gilead Sciences, Inc. <div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div>
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
CN101778855A (zh) * 2007-05-22 2010-07-14 阿尔迪默菲克斯技术有限责任公司 替诺福韦酯半富马酸共晶体
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
PL2296633T3 (pl) 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
AP3250A (en) 2009-02-06 2015-05-31 Gilead Sciences Inc Tablets for combination therapy
EA201200525A1 (ru) 2009-09-21 2012-09-28 Гайлид Сайэнсиз, Инк. 2'-фторзамещенные карба-нуклеозидные аналоги для противовирусного лечения
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
AP3816A (en) 2010-11-19 2016-09-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Also Published As

Publication number Publication date
SG10201912527XA (en) 2020-02-27
AR123409A2 (es) 2022-11-30
WO2012068535A1 (en) 2012-05-24
CA2818097A1 (en) 2012-05-24
AU2016208417B2 (en) 2018-04-05
AP2013006931A0 (en) 2013-06-30
UA114075C2 (xx) 2017-04-25
US10857102B2 (en) 2020-12-08
EA025852B1 (ru) 2017-02-28
RS53691B1 (sr) 2015-04-30
JP2015131853A (ja) 2015-07-23
PE20140163A1 (es) 2014-02-08
MX347512B (es) 2017-04-28
CO6761300A2 (es) 2013-09-30
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
JP2014500261A (ja) 2014-01-09
SG10201509521WA (en) 2015-12-30
CA2818097C (en) 2019-07-30
EP2826466A1 (en) 2015-01-21
MY185604A (en) 2021-05-25
EA201390651A1 (ru) 2013-11-29
TW201238612A (en) 2012-10-01
AU2016208417A1 (en) 2016-08-18
EA201691695A1 (ru) 2017-11-30
NZ610729A (en) 2015-10-30
MA34735B1 (fr) 2013-12-03
BR112013012245A2 (pt) 2016-08-09
PT2640362E (pt) 2014-11-28
PH12013501002A1 (en) 2013-09-09
DK2640362T3 (en) 2014-12-01
PL2640362T3 (pl) 2015-03-31
ES2524408T3 (es) 2014-12-09
CR20130293A (es) 2013-10-03
SMT201400150B (it) 2015-01-15
CN103491948A (zh) 2014-01-01
HK1206592A1 (en) 2016-01-15
EP2640362B2 (en) 2021-12-01
EP2640362A1 (en) 2013-09-25
BR112013012245B1 (pt) 2022-09-27
CN103491948B (zh) 2016-11-02
ME01980B (me) 2015-05-20
PE20211657A1 (es) 2021-08-24
KR20140037799A (ko) 2014-03-27
HK1190064A1 (en) 2014-06-27
TWI556840B (zh) 2016-11-11
AP3816A (en) 2016-09-30
PE20170521A1 (es) 2017-05-27
US20130243857A1 (en) 2013-09-19
AU2011329642A1 (en) 2013-05-02
CL2013001402A1 (es) 2013-12-27
AU2018202635A1 (en) 2018-05-10
KR101923103B1 (ko) 2018-11-28
SG190333A1 (en) 2013-06-28
ZA201304481B (en) 2022-03-30
HRP20140946T1 (hr) 2015-02-13
ES2524408T5 (es) 2022-04-25
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
EP2640362B1 (en) 2014-09-10
MX2013005669A (es) 2013-11-04
JP6138851B2 (ja) 2017-05-31
ECSP13012700A (es) 2013-08-30
IL226300B (en) 2019-05-30
PL2640362T5 (pl) 2022-05-02

Similar Documents

Publication Publication Date Title
AR084500A1 (es) Tableta multicapa para tratar la infeccion por hiv en un humano
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
MX2024010140A (es) Nuevos metodos.
PH12013501994A1 (en) Controlled release pharmaceutical dosage forms
USD727498S1 (en) Surgical foot pedal
EA201291158A1 (ru) Комбинированные вакцины с синтетическими наноносителями
CO2017013293A2 (es) Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
MX2018005729A (es) Composiciones terapeuticas para tratamiento del virus de inmunodeficiencia humana.
CL2011001885A1 (es) Tableta bicapa oral en donde la primera capa comprende al compuesto de formula i (elvitegravir) y al compuesto de formula ii, y la segunda capa comprende al compuesto de formula iii (emtricitabina) y a la sal de formula iv (sal de tenofovir); metodo para la preparacion, util en el tratar infecciones por vih.
NZ738524A (en) Pharmaceutical formulations comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine
PE20110119A1 (es) Asociacion entre ferroquina y artesunato para el tratamiento del paludismo
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
IN2013CH05288A (es)
PE20151282A1 (es) Combinacion de medicamentos que comprenden fenilefrina y paracetamol
AR129894A2 (es) Formas de dosificación de liberación prolongada para un inhibidor de jak 1
AR125919A2 (es) Formas de dosificación de ruxolitinib de liberación sostenida
TH171908A (th) องค์ประกอบบำบัดที่ประกอบรวมด้วย ริลพิวิรีน HCL (rilpivirine HCL) และ เทโนโฟเวียร์ ไดโซพรอกซิล ฟิวมาเรต (tenofovir disoproxil fumarate)
MX355000B (es) Composición farmacéutica en microesferas con antihistamínico no sedante y antiemético.
AR106645A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
MX2010006317A (es) Composicion farmaceutica oral con antihistaminico y descongestionante.
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos
AR098884A1 (es) Alteraciones de activación de notch en el cáncer de mama
UA111923U (uk) Спосіб лікування проявів опіатного абстинентного синдрому

Legal Events

Date Code Title Description
FC Refusal